文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

维奈克拉治疗异基因造血干细胞移植后复发恶性血液病25例的疗效与安全性

[Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

回顾性分析2021年2月至2021年11月中国医学科学院血液病医院25例allo-HSCT后复发患者,15例MRD阳性者接受抢先治疗、10例形态学复发者接受挽救治疗,VEN剂量均为400 mg/d(联合唑类抗真菌药时减至100 mg/d)。抢先治疗组ORR为80%(12/15),挽救治疗组ORR为60%(6/10);1疗程未获主要反应者OS率显著低于获得主要反应者。

要点

  • allo-HSCT后MRD阳性抢先治疗组VEN 1疗程ORR为80%(12/15),8例MRD转阴。
  • 形态学复发挽救治疗组VEN 1疗程ORR为60%(6/10),CR 3例、PR 3例。
  • 1疗程VEN未获主要反应者OS率(36.2±14.7)%,低于获得主要反应者的(90.9±8.7)%(P=0.009)。

核心结论

  • VEN对allo-HSCT后复发恶性血液病患者进行抢先/挽救治疗有一定疗效且耐受性良好,监测VEN血药浓度有望提高疗效。
  • VEN抢先/挽救治疗1个疗程未获得主要反应的患者预后较差,需尽早转换其他治疗方案。

研究设计与样本

  • 回顾性分析2021年2月至2021年11月在中国医学科学院血液病医院接受VEN治疗的25例allo-HSCT后复发恶性血液病患者临床资料。
  • MRD阳性患者15例为抢先治疗组,形态学复发患者10例为挽救治疗组;两组VEN剂量均为400 mg/d,联合唑类抗真菌药物时减量至100 mg/d。

主要发现

  • 抢先治疗组男7例、女8例,中位年龄32(18~52)岁,AML 13例、ALL 1例、PMF 1例;MRD阳性至应用VEN中位时间2.5(0~12.5)个月,VEN中位疗程2(1~4)个,第1疗程第7天VEN中位血药浓度1 945(688~5 383)μg/L;1疗程后8例MRD转阴、4例MRD较治疗前下降50%、3例无效,ORR 80%(12/15)。
  • 抢先治疗组9例第7天VEN血药浓度<1 000 μg/L或>3 000 μg/L患者中3例(33.3%)MRD转阴,6例血药浓度1 000~3 000 μg/L患者中5例(83.3%)MRD转阴;5例(33%)出现3/4级中性粒细胞减少,5例(33%)出现3/4级血小板减少,无新发严重感染致死病例。
  • 挽救治疗组男7例、女3例,中位年龄44(28~59)岁,AML 6例、ALL 2例、aCML 1例、MDS-RCMD 1例;复发至应用VEN中位时间0(0~1)个月,VEN中位疗程1(1~2)个,第1疗程第7天VEN中位血药浓度2 419(1 200~6 155)μg/L;1疗程后3例CR、3例PR、4例无效,ORR 60%(6/10);4例血药浓度>3 000 μg/L患者中1例CR,6例血药浓度1 000~3 000 μg/L患者中2例CR;10例(100%)均出现3/4级中性粒细胞减少及3/4级血小板减少,1例死于严重肺感染。
  • 中位随访4.5(1~8.5)个月,抢先治疗组与挽救治疗组OS率分别为(70.2±12.7)%与(50.0±15.8)%(χ²=1.873,P=0.171);1疗程VEN获得主要反应与未获得主要反应患者OS率分别为(90.9±8.7)%与(36.2±14.7)%(χ²=6.843,P=0.009);3例TP53突变患者VEN治疗后均获得主要反应。

关键数值与推荐

  • 抢先治疗组1疗程后ORR 80%(12/15),其中MRD转阴8例、MRD下降50% 4例;第7天VEN血药浓度1 000~3 000 μg/L者MRD转阴5/6(83.3%),<1 000 μg/L或>3 000 μg/L者MRD转阴3/9(33.3%)。
  • 挽救治疗组1疗程后ORR 60%(6/10),其中CR 3例、PR 3例;血药浓度>3 000 μg/L者CR 1/4,1 000~3 000 μg/L者CR 2/6。
  • 抢先治疗组与挽救治疗组OS率分别为(70.2±12.7)%与(50.0±15.8)%(P=0.171);1疗程获得与未获得主要反应者OS率分别为(90.9±8.7)%与(36.2±14.7)%(P=0.009)。

临床怎么用

  • 作者认为应用VEN对allo-HSCT后复发恶性血液病患者进行抢先/挽救治疗有一定疗效且耐受性良好,监测VEN血药浓度有望提高疗效。
  • 作者认为VEN抢先/挽救治疗1个疗程未获得主要反应的患者预后较差,需尽早转换其他治疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objegtive: To investigate the efficacy and safety of preemptive/salvage therapy with venetoclax (VEN) in patients with recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Methods: Retrospective analysis the clinical data of 25 patients with minimal residual disease (MRD) positive or morphological recurrence after allo-HSCT treated with VEN in the hematological Hospital of Chinese Academy of Medical Sciences from 2021.2 to 2021.11, there were 15 MRD positive patients (preemptive treatment group) and 10 morphological recurrence patients (salvage treatment group) . The dose of VEN in both groups was 400 mg/d, which was reduced to 100 mg/d when combined with azole antifungal drugs. Results: ①In the preemptive group, there were 7 males and 8 females, with a median age of 32 (18-52) years; There were 13 cases of acute myeloid leukemia (AML) , 1 case of acute lymphoblastic leukemia (ALL) and 1 case of primary myelofibrosis (PMF) ; the median time from MRD positive to the application of VEN was 2.5 (0-12.5) months. The median course of treatment was 2 (1-4) . On the 7th day of the first course of treatment, the median concentration of VEN was 1945 (688-5383) μg/L. After one course of VEN treatment, MRD in 8 patients turned negative (major responses) , MRD in 4 patients decreased by 50% compared with that before treatment, 3 cases were ineffective, and the overall response rate (ORR) was 80% (12/15) . On the 7th day of treatment, 3 of the 9 patients with VEN blood concentration <1 000 μg/L or >3 000 μg/L turned negative for MRD (33.3%) , and 5 of the 6 patients with VEN blood concentration between 1000 and 3000 μg/L turned negative for MRD (83.3%) . Grade 3/4 neutropenia occurred in 5 patients (33%) and grade 3/4 thrombocytopenia occurred in 5 patients (33%) , there were no new cases of severe infection and death. ②In the salvage group, there were 7 males and 3 females, with a median age of 44 (28-59) years; there were 6 cases of AML, 2 cases of ALL, 1 case of atypical chronic myeloid leukemia (aCML) , 1 case of refractory hemopenia with multiline dysplasia (MDS-RCMD) ; the median time from relapse to application of VEN was 0 (0-1) months. The median treatment was 1 (1-2) course. The median concentration of VEN on the 7th day of the first course of treatment was 2 419 (1 200-6 155) μg/L. After one course of VEN treatment, 3 cases achieved complete remission (CR) (major responses) and 3 cases achieved partial remission (PR) , 4 cases were ineffective and the ORR was 60% (6/10) . On the 7th day of treatment, 1 of the 4 patients with VEN blood concentration >3 000 μg/L achieved CR (25%) , and 2 of the 6 patients with VEN blood concentration between 1 000 and 3 000 μg/L achieved CR (33.3%) . Grade 3/4 neutropenia and grade 3/4 thrombocytopenia occurred in 10 patients (100%) . One patient died of severe pulmonary infection. ③The median follow-up was 4.5 (1-8.5) months. The overall survival rate (OS) of the preemptive group and the salvage group were (70.2±12.7) % and (50.0± 15.8) %, respectively (χ(2)=1.873, P=0.171) . The OS of patients with and without primary response to one course of VEN were (90.9±8.7) % and (36.2±14.7) % respectively (χ(2)=6.843, P=0.009) . Three patients with TP53 mutation achieved the major responses after VEN treatment. Conclusion: Preemptive/salvage therapy with VEN after allo-HSCT in patients with hematological malignancies is effective and well tolerated, monitoring the concentration of VEN is expected to improve the curative effect. The prognosis of patients who fail to reach the major responses after one course of preemptive/salvage treatment with VEN is poor, so they need to switch to other treatment schemes as soon as possible. 目的: 观察维奈克拉(VEN)治疗异基因造血干细胞移植(allo-HSCT)后复发恶性血液病患者的疗效及安全性。 方法: 回顾性分析2021年2月至2021年11月在中国医学科学院血液病医院接受VEN治疗的25例allo-HSCT后复发患者的临床资料,其中微小残留病(MRD)阳性患者15例(抢先治疗组),形态学复发患者10例(挽救治疗组)。两组VEN剂量均为400 mg/d,联合唑类抗真菌药物时减量至100 mg/d。 结果: ①抢先治疗组男7例,女8例,中位年龄32(18~52)岁;急性髓系白血病(AML)13例,急性淋巴细胞白血病(ALL)1例,原发性骨髓纤维化(PMF)1例;MRD阳性至应用VEN中位时间为2.5(0~12.5)个月。VEN中位疗程数为2(1~4)个。第1疗程治疗第7天VEN中位血药浓度为1 945(688~5 383)μg/L。VEN治疗1疗程后8例患者MRD转为阴性(获得主要反应),4例MRD较治疗前下降50%,3例无效,总体反应率(ORR)为80%(12/15)。9例治疗第7天VEN血药浓度<1 000 μg/L或>3 000 μg/L患者中3例(33.3%)MRD转阴,6例VEN血药浓度1 000~3 000 μg/L患者中5例(83.3%)MRD转阴。5例患者出现3/4级中性粒细胞减少,5例患者出现3/4级血小板减少,无新发严重感染致死病例。②挽救治疗组男7例,女3例,中位年龄44(28~59)岁;AML 6例,ALL 2例,不典型慢性髓性白血病(aCML)1例,骨髓增生异常综合征难治性血细胞减少伴有多系发育异常(MDS-RCMD)1例;复发至应用VEN中位时间为0(0~1)个月;VEN中位疗程数为1(1~2)个;第1疗程治疗第7天VEN中位血药浓度为2 419(1 200~6 155)μg/L。VEN治疗1疗程后3例获得完全缓解(CR)(主要反应),3例获得部分缓解(PR),4例无效,ORR为60%(6/10)。4例治疗第7天VEN血药浓度>3 000 μg/L患者中1例获得CR,6例VEN血药浓度1 000~3 000 μg/L患者中2例获得CR。10例患者均出现3/4级中性粒细胞减少及3/4级血小板减少。1例患者因严重肺感染死亡。③中位随访4.5(1~8.5)个月,抢先治疗组、挽救治疗组总生存(OS)率分别为(70.2±12.7)%、(50.0±15.8)%(χ(2)=1.873,P=0.171)。1疗程VEN治疗获得主要反应、未获得主要反应患者的OS率分别为(90.9±8.7)%、(36.2±14.7)%(χ(2)=6.843,P=0.009)。3例存在TP53突变的患者在VEN治疗后均获得主要反应。 结论: 应用VEN对allo-HSCT后复发的恶性血液病患者进行抢先/挽救治疗有一定疗效且耐受性良好,监测VEN血药浓度有望提高疗效。VEN抢先/挽救治疗1个疗程未获得主要反应的患者预后较差,需尽早转换其他治疗方案。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Chen X, Liu ZY, Zhang RL, et al. [Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 36709130. doi:10.3760/cma.j.issn.0253-2727.2022.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。